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Abstract
Background: Aberrant activation of fibroblast growth factor receptors (FGFRs) deregulates cell proliferation and
promotes cell survival, and may predispose to tumorigenesis. Therefore, selective inactivation of FGFRs is an important
strategy for cancer therapy. Here as a proof-of-concept study, we developed a FGFR1 neutralizing antisera, IMB-R1,
employing a novel strategy aimed at preventing the access of essential heparan sulfate (HS) co-receptors to the
heparin-binding domain on FGFR1.
Methods: The mRNA and protein expression level of FGFR1 and other FGFRs were examined in several lines of breast
cancer and osteosarcoma cells and corresponding normal cells using Taqman real-time quantitative PCR and Western
blot analysis. The specificity of IMB-R1 against FGFR1 was assessed with various ELISA-based approaches and Receptor
Tyrosine Kinase array. Proliferation assay and apoptosis analysis were performed to assess the effect of IMB-R1 on
cancer cell growth and apoptosis, respectively, in comparison with known FGFR1 inhibitors. The IMB-R1 induced
alteration of intracellular signaling and gene expression were analysed using Western blot and microarray approaches.
Immunohistochemical staining of FGFR1 using IMB-R1 were carried out in different cancer tissues from clinical patients.
Throughout the study, statistical differences were determined by Student’s t test where appropriate and reported
when a p value was less than 0.05.
Results: We demonstrate that IMB-R1 is minimally cross-reactive for other FGFRs, and that it potently and specifically
inhibits binding of heparin to FGFR1. Furthermore, IMB-R1 blocks the interaction of FGF2 with FGFR1, the kinase activity
of FGFR1 and activation of intracellular FGFR signaling. Cancer cells treated with IMB-R1 displayed impaired FGF2
signaling, were unable to grow and instead underwent apoptosis. IMB-R1-induced cell death correlated with a
disruption of antioxidative defense networks and increased expression of several tumor suppressors and apoptotic
proteins, including p53. Immunostaining with IMB-R1 was stronger in human cancer tissues in which the FGFR1 gene is
amplified.
Conclusion: Our study suggests that blocking HS interaction with the heparin-binding domains of FGFR1 inhibited
cancer cell growth, which can be an attractive strategy to inactivate cancer-related heparin-binding proteins.
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Background
Cancer is the leading cause of death worldwide, account-
ing for around 13 % of all fatalities, with mortality numbers
continuing to rise. Cancer therapy is one of the fastest
growing segments in the pharmaceutical industry, which it-
self is undergoing a major shift from conventional chemo-
therapy and radiotherapy to specific agents aimed at
targeting abnormalities that are specific to cancer cells.
Amongst these are dysregulations of crucial growth fac-
tor cascades.
Fibroblast growth factors (FGFs) are pivotal regulators
to key cellular processes, and their deregulation can lead
to excessive proliferation, evasion of apoptosis, invasive
behavior as well as aberrant angiogenic responses, all
hallmarks of cancer. FGFs and their receptors (FGFRs)
have been shown to be oncogenes in mouse tumor models
[1] and their over-expression or over-activation have been
observed in many cancers [2–4]. Of the over 500 pathways
that have been implicated in oncogenic cascades, the ki-
nases in FGF signaling are the most commonly mutated
[5]. FGFs and FGFRs have thus become important targets
for cancer intervention.
Research laboratories and pharmaceutical companies
have been developing FGFR tyrosine kinase inhibitors
(TKIs), antibodies against FGFRs and inactive receptor
decoys as targeted cancer therapeutics. Several of the
TKIs are undergoing clinical trials. However, most of these
compounds are nucleotide analogs that have multiple tar-
gets due to similarity in structure of the intracellular kin-
ase domains of FGFRs with vascular endothelial growth
factor receptors (VEGFRs) and platelet-derived growth
factor receptors (PDGFRs), as well as off-target inhibition
of other proteins. Thus, recent efforts have focused on de-
veloping more specific FGFR TKIs, as well as neutralizing
antibodies that are more specific than chemical inhibitors,
particularly antibodies that target individual FGFR iso-
forms, so avoiding pan-FGFR inhibition [6]. Antibodies
against FGFRs have been reported to inhibit tumor growth
in xenograft models [7–9].
The family of FGFRs, consisting of four members
(FGFRs1-4), are highly conserved, sharing 55–72 % amino
acid sequence with each other [10]. FGFRs1 - 3 are widely
expressed in adult human tissues, with FGFR4 exhibiting
more limited tissue distribution [11]. The extracellular re-
gion of most FGFRs contains three immunoglobulin-like
motifs (Ig domains). Alternative splicing of FGFRs1-3
mRNA transcripts within the IgIII domain results in
two isoforms, IIIb and IIIc, which have altered affinity
for FGFs and exhibit tissue-specific expression. The IIIb
isoform is expressed mainly in epithelium and the IIIc
in mesenchyme [12]. A heparin-binding domain, essen-
tial for interactions with heparin/heparan sulfate (HS),
is located between IgII and IgIII [13]. FGFs are known
to bind to the IgII and IgIII domains on FGFRs [14],
triggering dimerization that subsequently activates intra-
cellular tyrosine kinase activity and downstream signaling.
Ubiquitously distributed on cell surfaces and within
the pericellular and extracellular matrix (ECM), HS is a
highly complex molecule consisting of varying lengths of
sulfated polysaccharides, some of which regulate growth
factor signaling in a relatively specific manner through
association with heparin-binding domains located on the
ligand and/or receptor [15, 16]. HS is required to stabilize
the FGF-FGFR interaction [17, 18] through the formation
of an FGF:HS:FGFR ternary complex [14, 19].
Active mutations of FGFR2 or FGFR3 are common in
various cancers [20], whereas the oncogenic impetus of
FGFR1 results mainly from either gene amplification or
overexpression of wild-type receptor [21–23]. FGFR1 over-
activation occurs frequently in breast [24] and prostate
cancer [25], with changes also reported in oral squamous
carcinoma, ovarian cancer and bladder cancer [15, 26, 27].
In this work we hypothesized that FGFR1 signaling might
be most effectively inhibited by blocking its interaction
with HS. An antibody (IMB-R1) was thus raised to mask
the heparin-binding domain on FGFR1. It proved to be
particularly effective in suppressing FGF signaling, indu-
cing strong apoptosis in cancer cells with tissue-specific
potency. Our study supports the idea that FGFs/FGFRs
are crucial for the survival of many cancer cells, and that
targeting FGFR1 is a rational and effective strategy for
therapy. More importantly, a novel strategy has been
opened up for the targeted therapy of many other growth
factor/receptors, that of preventing heparan sulfate/
protein interactions.
Results
Increases in FGFR1 mRNA and protein expression in
cancer cells
Previous studies have indicated that FGFRs are over-
expressed in cancer cells [28]. To check for expression
in cancers of both epithelial and mesenchymal origin,
we screened the expression of FGFR1-3 in human breast
cancer and osteosarcoma cell lines as well as their normal
counterparts—human mammary epithelial cells (MCF10A)
and human fetal osteoblasts (hFOBs). FGFR1 mRNA
transcripts were highly abundant in all cells tested, and sig-
nificantly more (~10-fold) than other FGFRs except in
T47D cells, where FGFR2 mRNA was detectable in slightly
greater amounts (Fig. 1a). Comparing these FGFR1 levels
with those in normal cells, we observed a significant in-
crease in MG63 (~3-fold) and up-regulation in all 3 breast
cancer lines (Fig. 1a and 1b). MG63 expressed the greatest
levels of FGFR1 transcripts of all the cells tested (Fig. 1a),
and was thus selected as the representative cancer cell
model in subsequent assays (Fig. 2e, 3b, 3d and 4a). Im-
portantly, FGFR1 protein was relatively overexpressed in
all cancer cells tested as compared with normal cells
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Fig. 1 Expression of FGFR1 in cells from breast and bone tissue. a, FGFR mRNA transcript levels in normal and cancer cells. b, Fold change in
FGFR mRNA based on expression in cancers cells relative to normal cells. c, FGFR protein levels in normal versus cancer cells. Results are from
triplicate experiments and the Western blot is representative of the triplicates. (*p < 0.05)
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(Fig. 1c). FGFR2 and FGFR3 were also up-regulated in
some of the cancer cells, but not as markedly as FGFR1
(Fig. 1c).
IMB-R1 specially bound and neutralized the activity of
FGFR1
The confirmation that FGFR1 is over-expressed in can-
cer cells prompted us to develop a neutralizing antibody
for FGFR1 intervention. Many studies have indicated
that the heparin-binding domains (HBD) within FGFRs
are important for FGF-FGFR interaction and subsequent
cell signaling [17, 18]. Thus we aimed to design an anti-
body, designated here as IMB-R1, to mask the HBD of
FGFR1 in order to compromise the ligand/receptor inter-
action (Additional file 1: Figure S1A). The 15 amino acid
sequence immediately upstream of the HBD was selected
Fig. 2 Specificity of IMB-R1 for FGFR1. a, Binding of IMB-R1 and MAB765 to FGFR1 isoforms (representative blot from triplicate experiments).
b, Affinity of IMB-R1 for FGFR isoforms (results are from triplicate experiments). c, Binding of FGFR to heparin in the presence or absence of
IMB-R1 (results are from triplicate experiments). d, Binding of FGF2 to FGFR in the presence or absence of IMB-R1 (results are from triplicate
experiments). e, FGFR phosphorylation stimulated by FGF2 in the presence or absence of IMB-R1 including the fold change of FGFR phosphorylation
as determined by a comparison of means






Fig. 3 Effects of FGFR1 inhibitors on cell growth. a, Fold change in cell number 48 h after treatment with IMB-R1. b, Temporal change in MG63 cell number
following treatment with IMB-R1 (1:250). c, Cell number following FGF2 treatment (20 ng/ml for MG63, 5 ng/ml for MDAMB468 and T47D) for 48 h. Cells were
pre-treatment with IMB-R1 for 1 h before FGF2 treatment. d, Cell number (MG63) following 48 h treatment with IMB-R1 or antigen-purified IMB-R1. e, Cell
numbers following 48 h treatment with varying doses of FGFR inhibitors. f, Cell numbers following 48 h treatment with the FGFR1 antibody
(MAB765) at varying doses. Unless otherwise stated, IMB-R1 was applied at a dilution of 1:250. All experiments were performed in triplicate
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Fig. 4 (See legend on next page.)
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as it both bears minimal homology to other FGFRs, and is
highly hydrophilic, and thus exposed when the protein is
in its native conformation [29]. FGFRs have multiple
splice variants, with the most common isoforms IIIb
(b) and IIIc (c) [30]. IMB-R1 recognized both isoforms,
unlike the commercially available neutralizing antibody
(MAB765), which only recognizes the b isoform (Fig. 2a).
IMB-R1 exhibited specificity for FGFR1 in an ELISA assay
employing recombinant human FGFR proteins. The af-
finity of IMB-R1 for FGFR1 dose-dependently increased
(irrespective of isoform), in contrast to its relatively low
affinity for FGFR2 and R3 (Fig. 2b). At the maximal di-
lution (1:1000), the affinity of IMB-R1 to FGFR1 was ~
3-fold higher than FGFR2 and ~29-fold higher than
FGFR3. The affinity of IMB-R1 for the FGFRs is at the
ratio of: FGFR1:FGFR2:FGFR3 = 29:9:1.
To verify that IMB-R1 prevented HS from docking, its
influence on heparin’s ability to bind directly to FGFRs
was assessed in a protein-GAG binding assay. IMB-R1
potently prevented the heparin-FGFR1 interaction, but
only slightly inhibited heparin binding to the other FGFRs
(Fig. 2c). At the highest dose (1:125), 67–78 % of the
heparin-FGFR1 interaction was blocked but less than 10
% of heparin-FGFR2 interaction and 27 % of the heparin-
FGFR3c interaction (Additional file 1: Figure S1B).
We next examined whether IMB-R1 could neutralize
FGFR1 activity. The effect of IMB-R1 on the FGF2-FGFR1
interaction was assessed by ELISA; IMB-R1 inhibited
FGF2 binding by up to 77 % to the FGFR1b isoform and
43 % to the FGFR1c isoform (Fig. 2d, Additional file 1:
Figure S1C). Notably, the effect of IMB-R1 on FGFR1
was more pronounced than on other FGFRs. FGFR phos-
phorylation was further examined in MG63 cells. IMB-R1
again reduced FGF2-stimulated phosphorylation of FGFR1
by 42 %, but only slightly (≈10 %) affected that of FGFR2
or FGFR3 (Fig. 2e). The enhanced phosphorylation of
FGFR3 in the presence of IMB-R1 was presumably due to
a compensation for the depressed FGFR1 signaling.
IMB-R1 inhibited basal and FGF2 stimulated cell growth
Inhibition of FGFR1 should block FGF-induced mito-
genic activity [31]; here IMB-R1 significantly inhibited
cell growth in a dose-dependent manner. At the median
dosage (1:250), IMB-R1 blocked growth in all the tested
cells, and wherever the fold change was less than 1, cell
numbers were less than those initially plated, suggesting
cell death (Fig. 3a). IMB-R1 was more detrimental to the
growth of normal osteoblasts (≥1:500 dilution) than osteo-
sarcoma cells (≥1:250 dilution). In contrast, it took higher
doses of IMB-R1 to kill normal breast cells (≥1:125 di-
lution) than breast cancer cells (≥1:250 dilution). Thus,
normal mammary gland cells can tolerate greater amounts
of IMB-R1 than cancer cells, with the opposite being true
for bone tissue. In all cells tested, the IC50 was at least
1:250 dilution, and this dosage was used for subsequent
studies. To eliminate a whole population requires a regi-
men of more than 6 days (Fig. 3b).
Further assessment demonstrated that IMB-R1 blocked
FGF2-stimulated cell proliferation. FGF2 dosage was pre-
determined as per Figure 5a. FGF2 increased cell prolifer-
ation rates in MG63 and T47D, and IMB-R1 completely
abrogated them (Fig. 3c). IMB-R1 inhibited the basal
proliferation of MDAMB468 cells; FGF2 at 5 ng/ml failed
to increase the growth of these cells (Fig. 3c) though in-
ducing a slight acceleration of BrdU intake which was
blocked by IMB-R1 (Additional file 1: Figure S2). In-
creasing doses of FGF2 did not change the outcome in
MDAMB468 cells (data not shown).
IMB-R1 is polyclonal antisera, albeit with good specifi-
city. Next, IMB-R1 was further antigen-affinity purified,
and two middle fractions, IMB-R1A and IMB-R1B, exam-
ined for their effects on proliferation. At 8 μg/ml, IMB-
R1B inhibited MG63 cell growth by 47 %, and IMB-R1A
by 30 % (Fig. 3d), indicating that the adverse effect of
IMB-R1 on cancer cells was in fact due to its anti-FGFR1
activity, and not any other, non-relevant component in the
sera.
IMB-R1 is more potent than other FGFR1-blocking agents
SU5402 and PD173074 are selective FGFR drug inhibi-
tors, frequently (especially SU5402) utilized to block the
tyrosine kinase activity of FGFRs [2]. The anti-FGFR1
antibody (clone # MAB765, R&D Systems) is one of the
very few neutralizing antibodies against FGFR1 that
have reached the market. The chemical inhibitors dose-
dependently blocked the growth of both normal and
cancer cells (Fig. 3e). The commercial FGFR1 antibody
failed to reduce the basal growth of MG63 cells, even at
doses up to 50 μg/ml (Fig. 3f ).
IMB-R1 induced cell apoptosis
To assess whether IMB-R1 could actively induce apop-
tosis, we next examined caspase 3 levels; it was induced
by IMB-R1 (at 1:250 dilution) in MG63 cells starting from
(See figure on previous page.)
Fig. 4 IMB-R1 induced cell apoptosis with varying potency. a, Caspase 3 activity was used as an assay for apoptosis in MG63 cells and the apoptotic
activity of IMB-R1 (1:250) compared with Staurosporine (15 nM). b, Cells were treated with either IMB-R1 or SU5402 for 24 h and stained with
a combination of Annexin V-FITC and PI to detect early apoptosis (positive for Annexin V-FITC, AV+/PI-) and late apoptosis (positive for both
Annexin V-FITC and PI, AV+/PI+). Total apoptotic level represents AV+/PI- plus AV+/PI+. FACS plots are representative of triplicate experiments,
and bar graphs show percentage cells in each population from triplicate experiments
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Fig. 5 (See legend on next page.)
Ling et al. Molecular Cancer  (2015) 14:136 Page 8 of 16
10–16 h after treatment, reaching a maximum (2.7-fold)
after 20 h (Fig. 4a, left panel). This apoptotic potency was
then compared to that of staurosporine, which is also
caspase-dependent [32]. Although staurosporine at 15 nM
was sufficient to induce caspase 3 activity in MG63 cells,
IMB-R1 at 1:250 was 3 times more potent (Fig. 4a, middle
and right panels).
Further apoptotic analysis was performed using an
Annexin V/PI dual staining approach in cells treated
with IMB-R1 or SU5402, a widely used FGFR chemical
inhibitor. Annexin V binds to phosphatidylserine, which
only appears at the early stage of apoptosis, whilst PI
can only stain cells at later stages of apoptosis. Therefore,
positive staining for Annexin V indicates early apoptosis,
whereas staining for both dyes suggests late apoptosis or
cell death. Unstained cells were first acquired for gating
purpose (data not shown). Both IMB-R1 and SU5402
treatment induced a significant shift in the cancer cell
population from left (viable) to right (apoptotic) within
the quadrant (Fig. 4b), indicating potent apoptotic activity.
However, IMB-R1 was less toxic to normal osteoblasts
and did not give rise to apoptosis in normal mammary
epithelial cells (Additional file 1: Figure S3). Compared
with the control, IMB-R1 gave rise to 2.6-fold more cell
death in osteosarcoma cells (MG63), 2.7-fold more in
breast cancer cells (MDAMB468 and T47D), 1.5-fold
more in normal osteoblasts (hFOBs), with no cell death
in normal mammary cells (MCF10A). Thus IMB-R1 ap-
pears more toxic to tumor cells than to healthy cells of
the same tissue. In contrast, SU5402 induced apoptosis
in both normal cells, being especially toxic for the
MCF10A (~88-fold) (Additional file 1: Figure S3). SU5402
caused double the level of cell death in MG63, and ~5-8
times more in MDAMB468 and T47D cells. Therefore, at
the dosages, SU5402 is less effective than IMB-R1 in kill-
ing osteosarcoma cells or certain breast cancer cells, and
is more toxic than IMB-R1 to healthy mammary cells.
IMB-R1 blocks FGFR1 signaling to downstream effectors
FGFR1 activation leads to the phosphorylation of an array
of kinases or enzymes that mediate several signaling cas-
cades [33–36]. FGF2 strongly activates two immediate ef-
fectors of FGFR1 in MG63 cells, FGFR substrate 2 (FRS2)
and phospholipase Cγ (PLCγ), as well as the downstream
extracellular signal-regulated kinases (ERK1/2) (Fig. 5a).
In contrast, the activation of Akt or protein kinase C
(PKC) was only minimal, confirming ERK is a major path-
way for FGF2 signaling in these cells. ERK pathways con-
trol cell proliferation and survival, also in breast cancer
cells exposed to FGF2 (Fig. 5a). However, in the presence
of IMB-R1, the FGF2-induced activity of this kinase was
greatly reduced (Fig. 5b).
U0126, a specific inhibitor of the upstream kinase of
ERKs, was used to confirm the above results. The dose
of U0126 required to completely shut down ERK signal-
ing was approximately 25 μM (Fig. 5c). At this dose,
U0126 induced significant cell death in all three cancer
cell lines, with fold-induction being 13.4, 2.4 and 1.3
for the MG63, MDAMB468 and T47D cells respectively
(Fig. 5d).
Next we studied the effect of IMB-R1 on proteins in-
volved in apoptosis or tumor progression. IMB-R1 in-
creased p53 levels in MG63, MCF10A and MDA-MB468
cells, and induced its phosphorylation in all cell types
(Fig. 5e). The cell cycle inhibitor p21 is a target gene of
p53. It was up-regulated by IMB-R1 in all cells tested.
Retinoblastoma protein (Rb) was increased by IMB-R1
in hFOBs and MG63 cells. MDAMB468 cells did not ex-
press Rb in our hands, which is consistent with a previous
report [37]. Thus Rb appeared to be a target molecule
for IMB-R1 in bone tissue but not in the breast tissue.
IMB-R1 also potently increased pro-apoptotic Bim pro-
tein levels in all the cells tested except the MDA-MB468.
Notably, c-Myc, whose role in apoptosis has been estab-
lished [38], was increased in all cells by IMB-R1.
The global effect of IMB-R1 on the gene expression in
cancer cells
To identify the mechanisms behind the apoptotic effect of
IMB-R1, we performed gene profiling analysis; distinct pro-
files were revealed between normal cells and cancerous
cells (Fig. 6a). With regard to the top 10 cellular functions
affected by IMB-R1, “cell death” ranked as the first for
MG63 cells and third for hFOBs, but last for the normal
MCF10A and this gene ontology category was not evident
for MDAMB468 cells (Fig. 6b). This again seems to confirm
that bone tissue is more sensitive to IMB-R1 than breast
tissue. Further analysis of the genes affected in common
between different sets of cell groups revealed other pertin-
ent gene lists (Fig. 6c, Additional file 1: Figure S4). The
nuclear factor E2-related factor 2 (NRF2) target genes heme
oxygenase (decycling) 1 (HMOX1), NAD(P)H:quinone
(See figure on previous page.)
Fig. 5 Downstream signaling targets of IMB-R1. Western blot analysis of signaling targets in serum-starved (SS) cells (48 h) released into FGF2 in
the absence (a) or presence (b) of IMB-R1 for the time points indicated. a, Following SS, cells were stimulated with FGF2 for 10 min and protein
expression determined. b, Following SS, cells were pre-treated with IMB-R1 (1:250 dilution) for 1, 2, 6 or 24 h then stimulated with 20 ng/ml
(MG63) or 5 ng/ml (T47D) of FGF2 for 10 min and protein expression determined. c, Cells were dosed with U0126 for 1 h and phosphorylated-ERKs
detected by immunoblotting. d, Cells were treated with U0126 for 24 h and stained with a combination of Annexin V-FITC and PI and presented as
per Figure 4 b. e, Cells were treated with IMB-R1 (1:250 dilution) for 48 h and the protein expression determined by immunoblotting
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oxidoreductase (NQO) 1 and glutamate-cysteine ligase
(GCL) M were up-regulated whereas glutathione peroxid-
ase (GPX) 1 and other selenoprotein genes (SEPW1,
SEPN1 or SEPP1) were down-regulated in both cancer
cells and normal cells (Fig. 6d, Additional file 1: Figure
S4). These genes mostly appeared in the top 20 gene
lists, suggesting NRF2- dependent and - independent anti-
oxidative defense predominantly contributed to FGF/
FGFR1-triggered cell survival (Fig. 6e), and served as the
key mechanism driving IMB-R1 induced cell death.
IMB-R1 recognizes FGFR1 in tumour biopsies
To determine the distribution of IMB-R1 in different can-
cers, IHC staining was performed on sections of nineteen
separate human cancer tissues as well as the adjacent nor-
mal tissue. After staining, the DAB substrate yielded a
dark brown end-product at the site of the target antigen,
with hematoxylin providing the counterstaining of cell nu-
clei in blue (Fig. 7a). In most tissues, the location of IMB-
R1 staining was in the cytoplasm. IMB-R1 staining was
significantly stronger in cancer cells in the breast, lung,
(See figure on previous page.)
Fig. 6 The effect of IMB-R1 on gene expression. Cells were treated with IMB-R1 (1:250 dilution) for 48 h and RNA extracted for microarray analysis.
a, The heatmaps: Red, up-regulation; Green, down-regulation. b, Top 10 affected cellular functions by IMB-R1 as determined by Ingenuity Pathway
Analysis. c, The number of common genes affected across the different cells. d, The antioxidant genes significantly regulated by IMB-R1. e, The
proposed signaling mechanisms disrupted by IMB-R1 during FGF2/FGFR1 dependent cell growth and survival in cancer cells
Fig. 7 IMB-R1 targets FGFR1 in multiple human cancers. a, IMB-R1 histochemical staining from a human cancer tissue array. Right panel, enlarged
image of boxed area highlighting increased FGFR1 expression (detected by IMB-R1) in breast cancer tissues from twenty separate donors compared
with adjacent healthy breast tissue. b, The intensity of FGFR1 expression (detected by IMB-R1) was scored and the average scores for the various cancer
tissues compared with those from adjacent healthy tissues
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lymphoma, esophagus, bladder and ovary tissues as well
as in melanoma cells compared to adjacent normal tissue,
suggesting FGFR1 expression is increased in these tumors
(Fig. 7b). Increased IMB-R1 staining was evident in inva-
sive ductal carcinoma cells compared to gland epithelial
cells in adjacent healthy tissue (Fig. 7a, right panel). This
finding is consistent with a previous report that FGFR1
gene amplification was observed in breast, ovarian, lung,
bladder and esophageal cancers [39]. Importantly, the
greater binding of IMB-R1 in these tumor tissues than
in the normal tissues indicated that IMB-R1 is able to
target malignant cells in these tissues/organs relatively
well over the adjacent normal cells.
Discussion
The growth of many aggressive tumors involves FGF
signaling which in turn is dependent on HS as an essential
‘co-receptor’. Here a highly specific FGFR1 antibody,
IMB-R1, was engineered in an attempt to prevent the
engagement of endogenous HS with FGFR1, so pre-
venting formation of an active FGF-HS-FGFR1 signal-
ing complex. The antibody recognizes specific epitopes
that are adjacent to the unique heparin-binding domain
within FGFR1, so disrupting the sugar-receptor associ-
ation. Thus, our approach differs markedly from other
strategies that have sought to block ligand-receptor in-
teractions by concentrating on the ligand-binding site.
Our approach not only yields a novel agent for preclinical
testing, but a novel way of blocking all HS-dependent in-
teractions involved in carcinogenesis.
Characterization of the mechanism of action of IMB-R1
demonstrated that it selectively affects cancer cell survival
by preventing the formation of FGF/FGFR1 complexes,
thereby inhibiting the FGF/FGFR1 signaling axis. This is
particularly important because heparin is known to facili-
tate FGF and FGFR1 dimerization [40], which has resulted
in attempts to modulate heparin’s action through compe-
tition with other carbohydrate compounds [41–44]. Ra-
ther than compete against heparin activity, here we sought
to block heparin binding and subsequent ligand/receptor
dimerization by using an antibody approach.
FGFR1 is one of the most widely expressed FGFRs [11],
and here we confirmed that FGFR1 is strongly expressed
in both normal and cancer tissues. We note that treatment
with IMB-R1 may result in altered levels of FGF-R1
expressed on the cell surface by interfering with FGF-2/
FGFR-1 binding and subsequent receptor endocytosis
(internalisation) [45]. FGFR1 mRNA and/or protein levels
are both significantly elevated in distinct cancers (e.g.,
breast and bone cancer), suggesting that the FGFR1 recep-
tor is a rational target for therapeutic intervention. We
found that normal mammary epithelial cells are less
sensitive to IMB-R1 than breast cancer cells, which in
turn suggests an antibody-based regime for preferential
elimination of breast cancer cells with minimal harm
towards normal mammary cells at the appropriate dos-
age is possible. However, this needs to be balanced against
the finding that normal osteoblastic cells are more sen-
sitive to IMB-R1 than osteosarcoma cells. Thus, the
antibody acts in a cell and tissue type -specific manner,
presumably due to differences in the relative expression
of FGFR1. The latter result, obtained with cultured cells,
provides a counter-indication for its utility in vivo.
Systemic administration of the IMB-R1 antibody might
exacerbate the osteolysis induced by metastatic breast
cancers. On the other hand, local delivery of the anti-
body into mammary gland tumors might prove effective
in constraining growth and thus offer a less invasive
therapy for inhibition of the primary breast tumor
mass.
We have used a variety of methods to determine the
mechanism by which the IMB-R1 antibody affects cell
survival. The cDNA microarray expression analysis indi-
cates that IMB-R1 consistently down-regulates the ex-
pression of proteins that contain selenocysteine (GPX1,
SEPP and SEPW), which are an important component of
antioxidant defense in human cells [46]. In view of their
protective role for tumor cells against oxidative insult,
and their overexpression in many cancer cells, seleno-
proteins have recently become targets for anti-cancer
therapies [47]. Suppressing selenoprotein expression leads
to increased oxidative stress in tumor cells and subsequent
apoptosis, which may also contribute to the observed
cancer cell growth arrest and death induced by IMB-R1.
Collectively, our data suggest that suppression of anti-
oxidants to induce apoptosis and inhibition of FGFR1-
dependent mitogenic activity may together represent
two principal mechanisms for the anti-oncogenic effects
of the IMB-R1 antibody.
As well as inactivation of selenoproteins, the data also
reveal that IMB-R1 increases the expression of the
HMOX1, NQO1 and GCLM. These and other genes are
downstream targets of the transcription factor NRF2,
which is a master transcriptional regulator of the oxida-
tive stress response. In normal cells, NRF2-mediated
mitigation of oxidative stress prevents cancer initiation
and progression by removing excessive ROS, so prevent-
ing DNA damage and avoiding spontaneous mutations
[48, 49]. However, one caveat for these beneficial cyto-
protective effects is that overactivation of NRF2 can be
oncogenic, through the survival of cancer cells that have
accumulated oxidative damage and genetic mutations [50,
51]. Importantly, FGF signaling is known to activate NRF2
to provide cytoprotection against oxidative stress [52].
Therefore, if our hypothesis is correct, IMB-R1 should
decrease the expression of NRF2-dependent genes.
To explain the paradoxical effects of IMB-R1 on sele-
noproteins and NRF2 target proteins, we suggest that
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the opposing expression profiles for the two classes of
anti-oxidant proteins may reflect regulatory feedback. The
IMB-R1 antibody might initially mediate suppression of
selenoproteins, triggering oxidative stress, which in turn
might induce NRF2 and activate the program of NRF2 -
responsive genes (HMOX1, NQO1 and GCLM). It ap-
pears that the reduction in selenoprotein expression
prevails, so inducing apoptosis upon IMB-R1 treatment.
Hence our data indicates that a key survival function of
FGFR1 is to support synthesis of selenoproteins. The
universal alteration of different groups of antioxidant
genes in opposing directions further indicate that IMB-
R1- induced cell death is a net outcome of unbalanced
oxidative insult vs antioxidative defense.
In specifically blocking signaling of FGF2/HS com-
plexes through FGFR1, IMB-R1 selectively affects cancer
cell survival and exhibits reduced non-specific toxicity
compared to chemical pathway inhibitors. This set of
attributes compares favorably with those of other FGFR
inhibitors, including SU5402 [53] and PD173074 [54],
both of which tend to be indiscriminately toxic to both
normal and cancer cells. The efficacy of IMB-R1 also com-
pares favorably to the commercial neutralizing FGFR1
antibody, MAB765 that failed to reduce the basal growth
of cancer cells. One limitation of this particular antibody
is that it is directed against the FGFR1 IIIb isoform,
which is preferentially expressed in epithelial cells. How-
ever, MAB765 does not antagonize the activity of the IIIc
isoform, the form which is expressed prominently in
mesenchymal cells. In contrast, IMB-R1 recognizes both
isoforms, so offering inhibition of FGFR1 signaling in can-
cers of either epithelial or mesenchymal origin. IMB-R1
differs from other existing FGFR1-neutralizing anti-
bodies in that it expressly disrupts HS-FGFR1 interactions,
highlighting the importance of targeting heparin-binding
sites as a potential anti-cancer strategy.
Conclusions
IMB-R1 differs from other existing FGFR1-neutralizing
antibodies in that it expressly disrupts HS-FGFR1 interac-
tions, highlighting the importance of targeting heparin-
binding sites as a potential anti-cancer strategy, not just




SU5402, Staurosporine and U0126 were obtained from
Merck. PD173074, protease inhibitor cocktails and other
chemicals were purchased from Sigma-Aldrich.
Cell culture
Cells were purchased from ATCC and maintained in
the corresponding recommended medium, except human
osteosarcoma cells (OS1) [55] that were cultured in
DMEM (1000 mg/L glucose) supplemented with 10 %
FCS, 2 mM L-glutamine, 25 mM HEPES (Biopolis Shared
Facility, A*STAR, Singapore) and antibiotics. Media changes
were performed every 2–3 days.
Taqman real-time quantitative PCR analysis
Cells were grown in triplicates and treated as indicated.
The mRNA expression of target genes were analysed
using the Taqman® real-time PCR method as described
previously [56]. Primers and probes were all pre-designed
by Applied Biosystems.
Western blot analysis
Cells were treated as indicated and lysed in Laemmli
buffer at 95 °C for 5 min. The denatured protein lysates
(~20 μl) were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and proteins transferred
to nitrocellulose membranes. The blots were divided
into three to five horizontal strips guided by protein
standards stained by Ponceau Red to permit analysis of
multiple proteins from the same sample without anti-
body stripping. Thereafter membranes were immuno-
blotted, protein targets visualized and their levels quantified
as described previously [56]. The p21 antibody was ob-
tained from BD Biosciences. The antibodies against FGFRs
or p53 were purchased from Santa Cruz. FGFR1 antibody
(#MAB765) was from R&D Systems. All other antibodies
were supplied by Cell Signaling Technology.
Antibody engineering
The peptide SSSEEKETDNTKPNR, located immediately
upstream of the heparin-binding domain of FGFR1, was
chosen as the antigen for the production of rabbit poly-
clonal FGFR1-neutralising antibodies as described pre-
viously [56]. The rabbit antiserum was designated as
IMB-R1, and was further affinity-purified using Reacti-
Gel beads (Thermo Scientific) coupled with the above
peptide. With this method we obtained two purified poly-
clonal antibodies, IMB-R1A and IMB-R1B, from two rabbit
sera.
Sandwich Enzyme-linked immunosorbent assay (ELISA)
Maxisorp™ EIA plates (Thermo Scientific) were coated
with 0.5 μg/ml goat anti-human IgG-Fc (Jackson Immuno-
Research Laboratories) in PBS at 4 °C overnight. Thereafter
the plate was blocked with 2 % bovine serum albumin
(BSA) for 1 h. Recombinant human FGFRs-Fc (R&D
systems) (500 ng/ml) or the control human IgG-Fc (Abcam)
was then added for 2 h, followed by incubation with
IMB-R1 or the control rabbit IgG (Invitrogen) at the in-
dicated doses for 1 h. The bound antibodies were de-
tected with 0.5 μg/ml HRP-conjugated goat anti-rabbit
IgG (Jackson ImmunoResearch Laboratories) and
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visualized with TMB substrate (Thermo Scientific). The
color was read at 450 nm using the Victor3 multilabel
plate reader (PerkinElmer). All reactions were per-
formed at room temperature, unless indicated other-
wise, and protected from light, with each step followed
by extensive washing in blocking buffer. The readings
were normalized against the controls.
Protein-GAG binding assay
To investigate whether IMB-R1 prevented heparin/HS
binding to FGFR1, 50 μg/ml heparin was coated onto
GAG-binding plates in the standard assay buffer provided
(Iduron). After blocked with 0.5 % BSA, the plate was
incubated with 2 μg/ml FGFR-Fc in PBS for 2 h at 37 °C.
FGFR-Fc bound to heparin was then detected using
0.5–1 μg/ml HRP-conjugated goat anti-human IgG-Fc
(Jackson ImmunoResearch Laboratories) for 1 h and vi-
sualized as described above.
To examine whether IMB-R1 affected the interaction
between FGFRs and FGF2, 5 μg/ml heparin was coated
onto the plate (using the standard assay buffer) as a sub-
strate to bind FGF2. The heparin-coated surface was
blocked with 0.5 % fish gelatin before 200 ng/ml FGF2
(R&D systems) in PBS was added for 2 h at 37 °C. Next,
FGFR-Fc (500 ng/ml) was pre-complexed in PBS with
increasing amounts of IMB-R1 (on ice for 2 h). The
complex was then applied to the FGF2 surface described
above for 1.5 h. The amount of FGFR-Fc bound to FGF2
was determined as described above.
Receptor Tyrosine Kinase array
The phosphorylation status of the FGFRs was determined
with the Human Phospho-Receptor Tyrosine Kinase Array
(R&D Systems). MG63 cells were seeded at 20,000 cells/
cm2 for 1 day and deprived of serum for 48 h before
treated with 20 ng/ml FGF2 in the presence of IMB-R1 or
rabbit IgG (at 1:250 dilution) for 5 min. The cells were then
rinsed with PBS and lysed with the buffer provided in the
kit. Cell lysates (250 μg) were assayed for of FGFR kinase
activity following the manufacturer’s instruction.
Proliferation assay
The cells were plated in triplicate at 20,000 cells/cm2
except for the MDAMB468 cells, that were at 100,000
cells/cm2. They were treated with indicated doses of
IMB-R1 or other reagents for 2 days, before viable cell
numbers were assessed by the GUAVA Flow Cytometry
Viacount Program as described previously [56].
Annexin V- propidium iodide (PI) staining
Cells were plated at the densities nominated above and
allowed to adhere overnight. Cells were treated with re-
agents for 24 h and then stained with Annexin V-FITC
and/or PI [46] protected from light for 15 min.. Fluorescent
cells were detected by BD FACS Array (BD Biosciences),
and viable and apoptotic cells analyzed using FlowJo soft-
ware (Tree Star Inc). The unstained cells were used for
gating purposes.
Caspase 3 activity assay
MG63 cells were seeded at 20,000 cells/cm2 and treated
as indicated. Cells were then lysed and Caspase 3 activ-
ity measured using the Caspase-3 Colorimetric Assay
Kit (BioVision) following the manufacturer’s instructions.
Microarray
Three consecutive passages of cells were treated as indi-
cated and the total RNA extracted in TRIzol®-reagent and
purified with the PureLink™ RNA mini kit (Invitrogen).
The purified RNA was processed to cRNA using the
Illumina® TotalPrep™-96 RNA Amplification kit (Ambion)
as per the manufacturer’s instructions. cRNA was hybrid-
ized to the probes on the Human HT-12 v4 Expression
BeadChip (Illumina). After washing and staining, the chip
was scanned by the BeadArray™ Reader. The data was
processed and heatmaps were generated using Genome-
Studio software. The gene expression data were further
analysed using GeneSpring GC 11.0 software and DAVID
Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov)
[57]. The function analysis was performed using Ingenuity
Pathways Analysis software. The overlapping of gene tar-
gets in different cells was analysed using VENNY software
(http://bioinfogp.cnb.csic.es/tools/venny/index.html).
Cancer tissue array
The human multiple organ cancer tissue array (US Biomax,
Inc) contains 19 types of cancer with 20 cases/type and 5
cases/type of normal controls. The sections were stained
with IMB-R1 using a standard immunohistochemistry
(IHC) paraffin staining method. The section was first
deparaffinized and heat-induced antigen retrieval per-
formed. After blocking in horse serum, the section was
incubated with IMB-R1 or rabbit serum at a dilution of
1:800 for 1 h. The bound IMB-R1 was detected with
ImmPRESS™ peroxidase anti-rabbit (Vector Laboratories)
for 30 min followed by addition of peroxidase substrate
DAB solution (DAKO Cytomation). Thereafter the section
was counterstained with Hematoxylin QS (Vector Labs)
and mounted in permanent mounting medium (Sigma).
All steps were performed at room temperature, and
between incubations sections were rinsed free of non-
specific binding. The total positive cell numbers and
intensity of the antibody staining were measured by
ImageScope (Aperio Scanning System) and 20x object
images captured. The intensity of staining was scored as
negative (0), weak (1+), moderate (2+), or strong (3+).
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Statistical analysis
Each experiment was repeated at least three times and
numeric data were expressed as mean ± SD of triplicate
samples. Differences among treatments were analyzed by
Student’s t test. Significant differences were considered
as those with a p value < 0.05.
Additional file
Additional file 1: Supplementary data. Figure S1. A, Proposed
interaction between IMB-R1 and FGFR1. B, Affinity of FGFR to heparin in
the presence or absence of IMB-R1 was presented as in Fig. 2b. The
percentage reduction of FGFR binding to heparin as determined by a
comparison of means was further calculated and shown as in the bar
graphs. C, Affinity of FGFR to FGF2 in the presence or absence of
IMB-R1 was shown in Fig. 2c. Here the percentage reduction of FGFR
binding to FGF2 as determined by a comparison of means was plotted as bar
graphs. Figure S2. The effect of IMB-R1 on the proliferation rate of cancer cells
were determined using 5-Bromo-2′- deoxyuridine (BrdU) incorporation assay.
Cells were plated at 20,000 cells/cm2 except MDAMB468 which were seeded
at 100,000 cells/cm2 and allowed to adhere overnight. Cell cycling was then
arrested by serum deprivation for 48 h. The quiescent cells were then treated
with IMB-R1 or vehicle for 1 h followed by FGF2 treatment (20 ng/ml for
MG63, 5 ng/ml for MDAMB468 and T47D) for another 24 h. Cells were
subsequently labeled with BrdU (Roche) for 3 h. The incorporated BrdU
was detected as per manufacturer’s instructions and the absorbance was
measured at 370 nm. Figure S3. The apoptotic effect of IMB-R1 and
SU5402 on normal osteoblast cells and normal mammary gland cells (hFOB
and MCF10A, respectively) were assessed as described in Fig. 4b. Figure S4.
The further analysis of microarray data described in Fig. 6. Genes affected in
all 4 cells, and the Top 20 common genes affected in various groups were
indicated.
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